Paper Details

  1. Home
  2. Paper Details

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Author: , BaumM, CawthornS, CoatesA, CuzickJ, EdwardsR, ForbesJ, HamedA, HowellA, PowlesT

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

Prophylactic tamoxifen reduces the risk of breast cancer by approximately 32% in women at increased risk. However, it is associated with a significant increase in thromboembolic events, particularly after surgery, and a non-significant increase in endometrial cancer. While mortality from non-breast-cancer causes is not increased, the overall risk to benefit ratio for the use of tamoxifen in prevention remains unclear.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side-effects associated with tamoxifen is unclear. METHODS: We und...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(02)09962-2

データ提供：米国国立医学図書館（NLM）

Tamoxifen for Breast Cancer Prevention: Results from the IBIS-I Trial

The field of oncology is constantly seeking new and effective strategies for preventing and treating cancer. This large-scale randomized controlled trial (IBIS-I) investigated the efficacy of tamoxifen in preventing breast cancer in women at increased risk. The researchers examined the incidence of breast cancer, including ductal carcinoma in situ, in women receiving tamoxifen compared to those receiving placebo. The study found that tamoxifen significantly reduced the risk of breast cancer by approximately one-third, highlighting its potential as a preventive agent for high-risk women. However, the study also identified an increased risk of thromboembolic events and deaths from all causes in the tamoxifen group, emphasizing the importance of careful risk-benefit assessment when considering tamoxifen for breast cancer prevention.

The Shifting Sands of Cancer Prevention: Tamoxifen and Breast Cancer Risk

This study provides valuable insights into the potential benefits and risks of tamoxifen for breast cancer prevention. The researchers found that tamoxifen significantly reduced breast cancer incidence in women at increased risk. However, they also identified an increased risk of thromboembolic events and deaths from all causes, emphasizing the importance of careful consideration and individualized risk-benefit assessment when considering tamoxifen for breast cancer prevention.

Navigating the Desert of Cancer Risk: Understanding Tamoxifen

This research, like a compass guiding travelers through a vast desert, provides valuable information for women and healthcare professionals considering tamoxifen for breast cancer prevention. The researchers highlight the potential benefits of tamoxifen in reducing breast cancer risk, but also caution about the associated risks, particularly thromboembolic events. This study underscores the importance of informed decision-making and personalized care when considering tamoxifen for breast cancer prevention.

Dr. Camel's Conclusion

This study, like a caravan traversing a vast desert, offers valuable insights into the use of tamoxifen for breast cancer prevention. The researchers demonstrate the potential benefits of tamoxifen in reducing breast cancer risk but also highlight the associated risks. This research underscores the importance of careful consideration and personalized risk-benefit assessment when considering tamoxifen for breast cancer prevention.

Date :
  1. Date Completed 2002-10-09
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

12243915

DOI: Digital Object Identifier

10.1016/s0140-6736(02)09962-2

Related Literature

Article Analysis
・Effects of tamoxifen
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.